The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 19, 2018

Filed:

Mar. 04, 2015
Applicants:

The General Hospital Corporation, Boston, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Daphne Winifred Bell, Chevy Chase, MD (US);

Daniel A. Haber, Chestnut Hill, MA (US);

Pasi Antero Janne, Newton, MA (US);

Bruce E. Johnson, Brookline, MA (US);

Thomas J. Lynch, Newton, MA (US);

Matthew Meyerson, Concord, MA (US);

Juan Guillermo Paez, Dean Funes, AR;

William R. Sellers, Chestnut Hill, MA (US);

Jeffrey E. Settleman, Newton, MA (US);

Raffaella Sordella, Bedford, MA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12Q 1/68 (2018.01); C12Q 1/48 (2006.01); G01N 33/574 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12Q 1/485 (2013.01); G01N 33/574 (2013.01); G01N 33/74 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/485 (2013.01); G01N 2800/52 (2013.01);
Abstract

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.


Find Patent Forward Citations

Loading…